BioCentury
ARTICLE | Distillery Therapeutics

Cancer

April 24, 2018 10:48 PM UTC

Cell culture studies suggest conjugates of pomalidomide and ALK inhibitors could help treat NSCLC and anaplastic large cell lymphoma (ALCL). The conjugates consist of the thalidomide analog Pomalyst pomalidomide linked to the small molecule ALK inhibitor Zykadia ceritinib or its parent compound TAE684. In human NSCLC and ALCL cell lines, the conjugates decreased proliferation compared with the unconjugated ALK inhibitors. Next steps could include testing the conjugates in animal models of cancer.

Celgene Corp. markets Pomalyst/Imnovid to treat multiple myeloma (MM)...